Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial

Core Points - Aethlon Medical, Inc. has initiated a clinical trial for the Hemopurifier® targeting patients with solid tumors who are not responding to anti-PD-1 therapies [1][2] - The trial aims to assess the safety, feasibility, and optimal dosing of the Hemopurifier in patients with stable or progressive disease during anti-PD-1 monotherapy [3] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device designed to treat cancer and life-threatening viral infections [4] - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [4] Clinical Trial Details - The trial will enroll approximately 18 patients and will monitor adverse events and changes in safety lab tests after a two-month run-in period of anti-PD-1 therapy [3] - Patients will receive 1, 2, or 3 Hemopurifier treatments over one week, with the study also examining the impact on extracellular vesicle (EV) concentrations [3] Research and Development - The Hemopurifier is designed to remove extracellular vesicles implicated in cancer spread and resistance to therapies, potentially improving response rates to anti-PD-1 antibodies [2][3] - Preclinical studies have shown the Hemopurifier's effectiveness in reducing exosome levels in cancer patient plasma [2]